Silence, MiReven in microRNA deal

Silence Therapeutics plc (LSE:SLN) partnered with MiReven Pty. Ltd. (Perth, Australia) to develop formulations of MiReven's microRNA-7 (miR-7) using Silence's lipid-based delivery technologies. The partners will evaluate the compound in models of prostate and lung cancers and melanoma. Silence will receive an undisclosed fee for the deal. MiReven said both parties will have a commercial interest in products from the deal but the company did not disclose details. On Wednesday, Silence was up 0.11p to 1.51p.

Silence will apply its AtuPLEX, DACC and DBTC delivery technologies. AtuPLEX delivers therapeutics to vascular endothelial cells, DACC delivers to the lung endothelium, and DBTC delivers to the liver. ...